Page 1

NEWS RELEASE charles river CHARLES RIVER LABORATORIES ANNOUNCES SECOND - QUARTER 2021 RESULTS - Second - Quarter Revenue of $ 914.6 Million - - Second - Quarter GAAP Earnings per Share of $ 1.72 and Non - GAAP Earnings per Share of $ 2.61 – - Increases 2021 Guidance - WILMINGTON , MA , August 4 , 2021 - Charles River Laboratories International , Inc. ( NYSE : CRL ) today reported its results for the second quarter of 2021. For the quarter , revenue was $ 914.6 million , an increase of 34.0 % from $ 682.6 million in the second quarter of 2020 . Acquisitions contributed 6.0 % to consolidated second - quarter revenue growth . The impact of foreign currency translation benefited reported revenue growth by 3.9 % . Excluding the effect of these items , organic revenue growth was 24.1 % , driven by contributions from all three business segments . The comparison to last year's COVID - 19 - related impact increased the reported and organic revenue growth rates in the second quarter of 2021 by 8.6 % and 8.0 % , respectively , with the greatest impact in the Research Models and Services segment . On a GAAP basis , second - quarter net income attributable to common shareholders was $ 88.4 million , an increase of 31.2 % from net income of $ 67.4 million for the same period in 2020 . Second - quarter diluted earnings per share on a GAAP basis were $ 1.72 , an increase of 28.4 % from $ 1.34 for the second quarter of 2020. The GAAP net income and earnings per share increases were primarily driven by higher revenue and operating margin improvement , partially offset by higher acquisition - related costs and a higher tax rate . In addition , the gain from the Company's venture capital and other strategic investments totaled $ 0.14 per share in the second quarter of 2021 , compared to a gain of $ 0.38 per share for the same period in 2020. The Company's venture capital and other strategic investment performance has been excluded from non - GAAP results . On a non - GAAP basis , net income was $ 133.8 million for the second quarter of 2021 , an increase of 68.1 % from $ 79.6 million for the same period in 2020. Second - quarter diluted earnings per share on a non - GAAP basis were $ 2.61 , an increase of 65.2 % from $ 1.58 per share for the second quarter of 2020. The non - GAAP net income and earnings per share increases were primarily driven by higher revenue and operating margin improvement . James C. Foster , Chairman , President and Chief Executive Officer , said , " The strength of our leading , non - clinical contract research and manufacturing portfolio was clearly demonstrated in our second - quarter financial performance . Robust industry fundamentals continue to drive 1